Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
ConclusionsIn DMARD-naive patients, apremilast monotherapy improved PsA signs/symptoms over 52 weeks and was generally well tolerated.Trial registrationClinicalTrials.gov (http://clinicaltrials.gov), NCT01307423.
Source: Rheumatology - Category: Rheumatology Source Type: research
More News: Arthritis | Diarrhoea | Disability | Headache | Laboratory Medicine | Migraine | Psoriasis | Psoriatic Arthritis | Respiratory Medicine | Rheumatology